SEC Form 4 · accession 0001179110-18-003163
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tracey L McCain
Officer — EVP and Chief Legal Officer
Period of report
Feb 27, 2018
Accepted (ET)
Mar 1, 2018 · 5:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 27, 2018 | M | 10,000 | $28.36 | A | 10,000 | D | |
| Common Stock | Feb 27, 2018 | S | 100 | $90.75 | D | 9,900 | D | |
| Common StockF3 | Feb 27, 2018 | S | 8,794 | $88.40 | D | 1,106 | D | |
| Common StockF4 | Feb 27, 2018 | S | 1,106 | $87.69 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $28.36 | Feb 27, 2018 | M | 10,000 | D | — | Oct 3, 2026 | Common Stock | 10,000 | 134,000 | D |
Explanation of responses
- F1The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- F2The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 18, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.90 to $88.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.47 to $87.85 per share.
- F5This option was granted on October 3, 2016. This option vested with respect to 25% of the shares underlying the option on September 6, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.